(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of 35.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Entrada Therapeutics's revenue in 2026 is $25,421,000.On average, 10 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,135,168,165, with the lowest TRDA revenue forecast at $0, and the highest TRDA revenue forecast at $2,411,911,719. On average, 10 Wall Street analysts forecast TRDA's revenue for 2027 to be $1,994,842,413, with the lowest TRDA revenue forecast at $953,738,805, and the highest TRDA revenue forecast at $3,416,874,935.
In 2028, TRDA is forecast to generate $2,301,538,045 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $7,034,742,514.